Valentina Rossi

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Emiliano Cocco, F. Javier Carmona, Pedram Razavi et al. · Science Signaling · 2018 · 73 citations · Full text

Medicine, Oncology, Pharmacology +17

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials

Valentina Rossi, Paola Berchialla, Diana Giannarelli et al. · Cancers · 2019 · 68 citations · Full text

Medicine, Oncology, Pharmacology +17

Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells

Daniela Pasquali, Valentina Rossi, Giovanni Conzo et al. · Journal of Molecular Endocrinology · 2008 · 63 citations · Full text

Medicine, Endocrinology, Oncology +17

“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome

Patrizia Vici, Laura Pizzuti, Isabella Sperduti et al. · Oncotarget · 2016 · 43 citations · Full text

Medicine, Oncology, Breast Oncology +7

Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptorα and β

Valentina Rossi, Giuseppe Bellastella, Claudio De Rosa et al. · Journal of Cellular Physiology · 2010 · 41 citations

Life Sciences, Oncology, Pharmacology +17